UBS Group
GDRX icon

UBS Group’s GoodRx Holdings GDRX Stock Holding History

UBS Group’s Portfolio GDRX Stock Details GDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Sell
454,795
-372,117
-45% -$946K ﹤0.01% 5496
2026
Q1 		$1.62M Buy
826,912
+159,465
+24% +$374K ﹤0.01% 5162
2025
Q4 		$1.81M Buy
667,447
+261,796
+65% +$859K ﹤0.01% 5068
2025
Q3 		$1.72M Buy
405,651
+130,711
+48% +$575K ﹤0.01% 5102
2025
Q2 		$1.37M Sell
274,940
-164,437
-37% -$714K ﹤0.01% 5168
2025
Q1 		$1.94M Buy
439,377
+205,978
+88% +$967K ﹤0.01% 4728
2024
Q4 		$1.09M Buy
233,399
+134,254
+135% +$738K ﹤0.01% 5239
2024
Q3 		$688K Sell
99,145
-372,311
-79% -$2.92M ﹤0.01% 4973
2024
Q2 		$3.68M Buy
471,456
+108,506
+30% +$804K ﹤0.01% 3152
2024
Q1 		$2.58M Buy
362,950
+350,643
+2,849% +$2.32M ﹤0.01% 3688
2023
Q4 		$82.5K Sell
12,307
-2,650
-18% -$14.9K ﹤0.01% 6288
2023
Q3 		$84.2K Sell
14,957
-272,077
-95% -$1.81M ﹤0.01% 5949
2023
Q2 		$1.58M Sell
287,034
-4,149
-1% -$22.3K ﹤0.01% 3762
2023
Q1 		$1.82M Sell
291,183
-294,417
-50% -$1.64M ﹤0.01% 3531
2022
Q4 		$2.73M Buy
585,600
+61,127
+12% +$301K ﹤0.01% 3070
2022
Q3 		$2.45M Buy
524,473
+34,710
+7% +$219K ﹤0.01% 2977
2022
Q2 		$2.9M Buy
489,763
+143,929
+42% +$1.6M ﹤0.01% 2825
2022
Q1 		$6.68M Buy
345,834
+21,515
+7% +$493K ﹤0.01% 2270
2021
Q4 		$10.6M Sell
324,319
-251,492
-44% -$10.1M ﹤0.01% 2091
2021
Q3 		$23.6M Sell
575,811
-233,950
-29% -$8.49M 0.01% 1372
2021
Q2 		$29.2M Sell
809,761
-143,875
-15% -$5.31M 0.01% 1202
2021
Q1 		$37.2M Buy
953,636
+451,376
+90% +$20.3M 0.01% 1024
2020
Q4 		$20.3M Buy
502,260
+492,239
+4,912% +$22.6M 0.01% 1337
2020
Q3 		$557K Buy
+10,021
New +$530K ﹤0.01% 4093

Other funds holding GDRX

FPM
Francisco Partners Management San Francisco, California $361M AUM 30.56% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PTC
Petrus Trust Company Dallas, Texas $1.06B AUM 4.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

UBS Group's GDRX Position: Q2 2026 in Review

UBS Group reduced its GoodRx Holdings (GDRX) stake by 45% in Q2 2026, selling an estimated $946K and leaving 454,795 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #5496.

UBS Group first reported a position in GDRX in Q3 2020 and has held it in 24 quarters since. The position peaked at $37.2M in Q1 2021. 162 funds tracked by Wall St. Rank hold GDRX as of Q2 2026.

  • UBS Group held 454,795 shares of GoodRx Holdings worth $1.31M as of Q2 2026.
  • UBS Group sold 372,117 GoodRx Holdings shares in Q2 2026, an estimated $946K.
  • GoodRx Holdings made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5496 holding.
  • UBS Group first reported a position in GoodRx Holdings in Q3 2020 and has held it in 24 quarters since.
  • UBS Group's GoodRx Holdings position peaked at $37.2M in Q1 2021.
  • 162 funds tracked by Wall St. Rank held GoodRx Holdings as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.